Interrogating the Role of Receptor-Mediated Mechanisms: Biological Fate of Peptide-Functionalized Radiolabeled Gold Nanoparticles in Tumor Mice
Authors:
- Francisco SilvaFSFrancisco Silva
- Ajit ZambreAZAjit Zambre
- Maria Paula Cabral CampelloMCMaria Paula Cabral Campello
- Lurdes GanoLurdes Gano
- Ana Maria FerrariaAna Maria Ferraria
- Maria João FerreiraMFMaria João Ferreira
- Amolak SinghASAmolak Singh
- Anandhi UpendranAUAnandhi Upendran
- António PauloAntónio Paulo
- Raghuraman KannanRKRaghuraman Kannan
- 7 April 2016
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 27 (4) , 1153-1164
Abstract
To get a better insight on the transport mechanism of peptide-conjugated nanoparticles to tumors, we performed in vivo biological studies of bombesin (BBN) peptide functionalized gold nanoparticles (AuNPs) in human prostate tumor bearing mice. Initially, we sought to compare AuNPs with thiol derivatives of acyclic and macrocyclic chelators of DTPA and DOTA types. The DTPA derivatives were unable to provide a stable coordination of 67Ga, and therefore, the functionalization with the BBN analogues was pursued for the DOTA-containing AuNPs. The DOTA-coated AuNPs were functionalized with BBN[7–14] using a unidentate cysteine group or a bidentate thioctic group to attach the peptide. AuNPs functionalized with thioctic-BBN displayed the highest in vitro cellular internalization (≈ 25%, 15 min) in gastrin releasing peptide (GRP) receptor expressing cancer cells. However, these results fail to translate to in vivo tumor uptake. Biodistribution studies following intravenous (IV) and intraperitoneal (IP) administration of nanoconjugates in tumor bearing mice indicated that the presence of BBN influences to some degree the biological profile of the nanoconstructs. For IV administration, the receptor-mediated pathway appears to be outweighed by the EPR effect. By contrast, in IP administration, it is reasoned that the GRPr-mediated mechanism plays a role in pancreas uptake.Keywords
Funding Information
- Wallace H. Coulter Foundation
- European Cooperation in Science and Technology (TD1004)
- Fundação para a Ciência e a Tecnologia (EXCL/QEQ-MED/0233/2012, PEst-OE/CTM/LA0024/2013, SFRH/BD/47308/2008, UID/Multi/04349/2013)
This publication has 60 references indexed in Scilit:
- Tuning Pharmacokinetics and Biodistribution of a Targeted Drug Delivery System Through Incorporation of a Passive Targeting ComponentScientific Reports, 2014
- EGF Receptor-Targeted Nanocarriers for Enhanced Cancer TreatmentNanomedicine, 2012
- Size Matters: Gold Nanoparticles in Targeted Cancer Drug DeliveryTherapeutic Delivery, 2012
- Beating cancer in multiple ways using nanogoldChemical Society Reviews, 2011
- A Reexamination of Active and Passive Tumor Targeting by Using Rod-Shaped Gold Nanocrystals and Covalently Conjugated Peptide LigandsACS Nano, 2010
- Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosisProceedings of the National Academy of Sciences, 2010
- Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificityProceedings of the National Academy of Sciences, 2010
- Gastrin Releasing Protein Receptor Specific Gold Nanorods: Breast and Prostate Tumor Avid Nanovectors for Molecular ImagingNano Letters, 2009
- Nanocarriers as an emerging platform for cancer therapyNature Nanotechnology, 2007
- Nanoparticle and targeted systems for cancer therapyAdvanced Drug Delivery Reviews, 2004